Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

OBJECTIVES: To investigate the possibility of discontinuing adalimumab (ADA) for 1 year without flaring (DAS28-erythrocyte sedimentation rate (ESR) ≥3.2), and to identify factors enabling established patients with rheumatoid arthritis (RA) to remain ADA-free. METHODS: Of 197 RA patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Hirata, Shintaro, Kubo, Satoshi, Fukuyo, Shunsuke, Hanami, Kentaro, Sawamukai, Norifumi, Nakano, Kazuhisa, Nakayamada, Shingo, Yamaoka, Kunihiro, Sawamura, Fusae, Saito, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316845/
https://www.ncbi.nlm.nih.gov/pubmed/24288014
http://dx.doi.org/10.1136/annrheumdis-2013-204016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316845/
https://www.ncbi.nlm.nih.gov/pubmed/24288014
http://dx.doi.org/10.1136/annrheumdis-2013-204016

Ejemplares similares